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Abstract 18 
Implementation of Quality by Design approaches in pharmaceutical industry requires a sound understanding of the parameters 19 
triggering final product variability. Excipients, although generally regarded as inert components, are of great significance in terms of 20 
solid dosage form development and any variation in the material attributes may impact drug product performance. Sourcing, 21 
production and processing are contributing factors to excipient variability. Interchange between different suppliers can lead to final 22 
products with different quality attributes. Identification of excipient critical material attributes is not straightforward, as criticality 23 
must be linked to functionality and it is well recognized that the mechanisms by which excipients exert their action are not fully 24 
understood. Investigating the impact of excipient variability on in vitro dissolution could enable scientists to get an insight on the in 25 
vivo behavior of drug products and potentially tolerate variability. A thorough understanding of excipient material properties, product 26 
components interactions and the effect of the gastrointestinal tract heterogeneity on excipients and drug release is recommended. This 27 
review aims to present current knowledge on excipient critical material attributes and their link to biopharmaceutical behavior and 28 
dissolution characteristics. Attempts to describe the impact of physiological conditions on excipient functionality are also addressed. 29 
Excipient properties that are considered crucial to drug product performance in a biorelevant perspective are elucidated. 30 
 31 
 32 
Keywords: Excipients; Dissolution; Solid Dosage Form; Solubility; Gastrointestinal; Polymers; Variability. 33 
34 
3 
 
1. Introduction 35 
Pharmaceutical development is now entering the new era of quality build. The traditional three batch validation is currently 36 
fading as batch failures, product recalls, drug shortages are still present in the pharmaceutical market. Regulatory agencies tend to 37 
impose more strict product specifications for new drug applications (NDAs), abbreviated new drug applications (ANDAs), biowaiver 38 
extensions and require a profound understanding of active pharmaceutical ingredient (API), excipient and product manufacturing, as 39 
well as, any interaction between these parameters that may affect final product safety and efficacy. In an attempt of amelioration, 40 
pharmaceutical industry is implementing the principles of Quality by Design (QbD). The aim is to build robust manufacturing 41 
processes in order to assure that the desirable product is constantly delivered to the patient through the establishment of a design space 42 
that defines the permissible area where variability and/or variations of input materials will not affect the outcome of the production 43 
process. Reducing or tolerating final product variation requires a profound understanding of all factors playing a crucial role in 44 
finished dosage forms. Controlling these crucial parameters will allow the design of products that will consistently meet final 45 
requirements, contribute to minimization of regulatory constraints and enable the safe passage from batch to continuous 46 
manufacturing, a beneficial production technique to address industrial deficiencies [1]. Excipients constitute a major component of 47 
final products and it is recognized that variability in their material properties can impact product processing, manufacturing and 48 
performance [2, 3]. The exact mechanisms by which excipients exert their action are still to be discovered, especially when drug 49 
product performance is concerned [4, 5]. The gastrointestinal heterogeneity and its effect on excipient functionality is an additional 50 
challenge in understanding and controlling the role of excipients in drug release. 51 
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A comprehensive overview of the current knowledge on excipient variability and its effect on solid dosage form performance 52 
is presented in this review. The biopharmaceutical parameters that impact the functional role of key excipients used in solid 53 
formulations is discussed. The aim is to gain a basic understanding of potential critical material attributes and their link to excipient 54 
and final drug product variability. 55 
2. Excipient variability in drug development 56 
As mentioned in the ICH Q8 “the aim of pharmaceutical development is to design a quality product and its manufacturing 57 
process to consistently deliver the intended performance of the product” [6]. A final dosage form should meet a number of 58 
specifications to justify its efficacy and safe use. Deviation from these acceptance criteria indicates variability of final dosage forms. 59 
Variation is difficult to control since random distribution prevails in everything [7]. QbD aims towards controlling variability by i. 60 
defining the final product attributes that will justify the intended use of final products and ii. deliberately designing the production 61 
process and establishing the design space and control strategy to always meet these final attributes. Aspects whose variability can 62 
compromise product quality are characterized by high criticality. Critical quality attributes refer to aspects of the output product while 63 
critical material attributes to input materials [8]. In terms of pharmaceutical development, factors that may trigger final product 64 
variability include: active pharmaceutical ingredients (APIs), excipients and process parameters [8]. The physicochemical properties 65 
of the two former, any deviations or alterations in the latter and the complex interplay of process parameters and material attributes 66 
contribute to the incline in quality specifications. It becomes clear that in order to control the outcome we must have a fundamental 67 
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understanding and control of all input materials. The required understanding of the reasons triggering product variability and batch 68 
failures is needed towards continuous pharmaceutical production and may not always be an easy task [9]. 69 
The impact of manufacturing processes on drug product quality has been addressed [10-12] but a more comprehensive 70 
approach towards drug product components is yet to be made. Examining the effect of input materials (e.g. APIs and excipients) on 71 
finished solid dosage forms requires a linkage of material properties to product quality attributes [13]. A thorough understanding of 72 
molecular, structural and particle properties of a substance is necessary. The limited knowledge on the role of physical and chemical 73 
properties of pharmaceutical components hinders the possibility to further optimize the behavior of oral solid dosage forms throughout 74 
manufacturing, but this gap is more pronounced in drug product performance. A change in a critical attribute for dissolution will not 75 
only cause production or regulatory failures, but it may strongly affect drug bioavailability. The complexity of the gastrointestinal 76 
environment adds a further challenge in investigating the effect of material attributes variability in drug dissolution. Although the API 77 
is considered the most substantial product component for disease treatment, it has to be noted that excipients can be more important in 78 
processes prior to oral drug absorption and also can induce even treatment failure if the drug is not appropriately released and 79 
dissolved according to product specifications. From manufacturing through to in vivo functional performance, excipients exert their 80 
action but their properties can affect drug dissolution, as it will be revealed by the critical analysis performed in this review. Since 81 
excipients constitute a large portion of a solid dosage form, comprising up to 99% of the total formulation mass [14], their impact on 82 
quality attributes can be statistically significant. The broad range of the excipient level used in solid dosage forms along with a 83 
possible alteration in excipient functionality by level variation, complicates further the excipient variability issue. In vitro and/ or in 84 
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vivo excipient effects on drug solubility, dissolution and permeability could impact oral bioavailability and bioequivalence. The use of 85 
a different type of excipient with the same intended functionality could also be problematic as the diversity of material properties may 86 
result in a change of the overall product performance. Understanding and integrating excipient variability in the production’s design 87 
space and control strategy will pave the way for building robust production processes both in batch and continuous manufacturing 88 
[15]. 89 
3. Sources of excipient variability 90 
Final product variability either preexists or is created during manufacturing. In this review, we are focusing on inherent 91 
excipient variability and its effect on final drug product. The main reasons for excipient variability are: i. raw material sourcing which 92 
includes environmental variations that may lead to different raw material properties and ii. manufacturing which refers to excipient 93 
variability caused by a change during excipient production and can be divided into inter and intra-supplier. 94 
Natural sourcing: The majority of excipients are naturally derived products or semi-synthetic compounds (produced after 95 
chemical modification of a natural product). They are bound, therefore, with inevitable variability caused by environmental alterations 96 
(natural, regional, seasonal) [16]. Sourcing of raw materials is a major factor for excipient variability. For example, microcrystalline 97 
cellulose can be produced by wood (softwood/hardwood) or cotton. A first study on four brands of microcrystalline cellulose (two 98 
brands derived from softwood and two from hardwood) examining lignin and hemicellulose content determined excipient origins. 99 
Significant variations in chemical structure, crystal structure and particle size were observed [17]. Differences in lignin content may be 100 
7 
 
the cause for the increased dissolution rate of prednisone tablets manufactured with microcrystalline cellulose from different sources 101 
[18]. Controlling the source of excipients can reduce variation but still any unavoidable natural complications may lead to production 102 
of different raw materials. 103 
Manufacturing: Excipients are manufactured by chemical companies for use in pharmaceutical, chemical, and food industry. 104 
A common strategy for pharmaceutical companies is to have more than one supplier in order to constantly meet market demands [14]. 105 
Changes in excipient supplier has been shown to contribute to excipient variability. Supplier to supplier variability may arise either 106 
from different natural sourcing or different manufacturing processes. For instance, significant intersupplier variability was observed in 107 
anhydrous lactose solid state properties (specific surface area, tensile strength, yield pressure) that could impact final dosage forms 108 
according to the amount of excipient used and the interplay with the other dosage form components [19]. Other examples of 109 
intersupplier variability are reporting differences in intrinsic viscosity, mean molecular weight, mean particle size and water uptake 110 
rate between two interchangeable Hydroxypropyl cellulose (HPC) brands [20], and in particle size and surface area between different 111 
magnesium stearate suppliers [21] . Although, intersupplier variability may seem more reasonable, intrasupplier variability referring to 112 
batch-to-batch or lot-to-lot variation in excipient production has been reported as well. A notable example of interlot excipient 113 
variability and its effect on final dosage form refers to a study by Perez et al. on lot to lot variability of Carbomer 943. The two 114 
dissimilar lots were found to greatly affect in vitro release rates of hydrochlorothiazide (HCTZ) matrix tablets, due to differences in 115 
mean molecular weight of carbomer [22]. Even a slight change in manufacturing procedures or parameters may have an effect on the 116 
product functionality. For example, two batches of soluble starch differing only in one additional washing step with acetone were 117 
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studied. Although, in terms of routine characterization the two batches were found identical, their compaction properties showed large 118 
variation due to their differences in the surface area caused by the extra washing step [23]. 119 
Inadequate specifications: Pharmacopeial specifications clearly address excipient identification but functionality 120 
specifications are not straightforward since excipient function is formulation/application dependent [3]. For instance, when 121 
hypromellose is used as a binder, viscosity and degree of substitution are considered functional properties, but additional properties 122 
(particle size distribution, powder flow) need to be controlled when the excipient is used as a release modifier [24]. Excipient demand 123 
is increased in the Food/Chemical/Cosmetic Industry,, and the quality tests prescribed to suppliers assuring excipient quality (identity, 124 
quality, purity) [3] focus mainly on their needs. This minimum of regulatory specifications may suffice for these industries, but 125 
pharmaceutical companies have to deal more strictly with excipient variability and be assured that the properties rendering excipients 126 
functional are “present” in every batch within appropriate limits. A first issue that arises from current monograph specifications is that 127 
they cannot adequately set the appropriate limits in functional specifications (“one-point” limits [25] or a wide range of acceptance 128 
values). Without prior mechanistic knowledge of the actual excipient role, variability could be detrimental, even if excipient property 129 
values meet monograph specifications [25]. The need for functional evaluation is encouraged with the introduction of Excipient 130 
Functionality Related Characteristics (FRCs) by the European Pharmacopeia and the General Information Chapter on “Excipient 131 
Performance <1059>” by the United States Pharmacopeia. Still, the terminology of excipient functionality is not straight-forward. The 132 
underlying mechanisms of excipient use in several cases are not known and further investigations are necessary in order to establish 133 
functionality tests, as excipient role should be addressed in case-by-case, function-by-function and product component interactive 134 
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perspective. The proposed FRC tests are not mandatory and mostly address chemical identification rather linking physical and 135 
chemical properties to excipient function [3]. Drug product manufacturers should gain a more thorough knowledge on excipient 136 
production and characteristics to get an insight when changing excipient suppliers in order to assure that excipient functionality and 137 
material properties remain consistent. 138 
4. Biopharmaceutical aspects of excipients 139 
Formulation scientists recognize the importance of excipient variability in drug product design. Reports in literature though 140 
address mainly drug product processing/manufacturability [26] and not drug product performance in terms of drug release from a solid 141 
dosage form and drug bioavailability. An interplay between in vitro conditions (i.e. dissolution medium composition, temperature, 142 
agitation) and in vivo physiological factors (i.e. gastrointestinal factors) and excipient functionality can impact drug bioavailability 143 
(Figure 1). Excipient presence in the luminal fluids triggers modifications in the gastrointestinal environment and gastrointestinal 144 
conditions may alter excipient material attributes leading to different functionality, with an effect in drug absorption in both cases. 145 
This strong interplay will complicate even more final product variability and bioequivalence, if not thorough investigated. 146 
4.1 Effect of excipients on physiological conditions 147 
Traditionally the effect of excipients, on drug product performance was considered of minor importance, due to their 148 
pharmacological inactivity. Only after the beginning of 90s, and with the foundation of the International Pharmaceutical Excipient 149 
Council (IPEC), investigation of their significance on finished drug products started [27]. An increased number of case studies 150 
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indicate that excipients may influence bioavailability and impede the establishment of bioequivalence between products. Novel 151 
formulations addressing the poor aqueous solubility of drugs, contain excipients that affect drug solubility, permeability (passive or 152 
active) and metabolism [28]. Solubilizers enhance the solubility of poorly soluble drugs and may decrease drug permeation through 153 
the intestinal epithelium due to the lower free drug fraction available for absorption [29]. A number of excipient classes have been 154 
demonstrated to affect tight junctions integrity [30], active transporters, [31, 32] and cytochrome P450 activity [33, 34]. Excipient 155 
effects on other physiological factors, e.g. gastric residence time, small intestinal transit time, mucus integrity, physiological pH and 156 
motility, have been extensively reviewed [35]. These interactions present a challenge on current considerations about the role of 157 
excipients on product performance and regulatory guidelines require extensive proofs of excipient inertness in each product [36, 37]. 158 
Biowaivers have been correlated to the Biopharmaceutical Classification System (BCS), and qualitatively and quantitatively similar 159 
excipients are required for biowaivers for immediate release formulations of BCS Class III compounds [37, 38]. According to WHO 160 
guidelines, an excipient can be used in multisource (generic) products requesting biowaiver even if it is not present in the comparator 161 
product, as long as it is present to other products containing the same API and have marketing authorization in countries participating 162 
in the International Committee of Harmonization [39]. Even in cases where excipients were not implied to affect bioequivalence, 163 
human bioavailability was altered with a change in the amount of an excipient or the addition of a new excipient in the generic product 164 
[40]. The addition of Sodium Lauryl Sulfate in a generic alendronate immediate release tablet (absent in the innovator alendronate 165 
(BCS III) tablet but present in generic alendronate tablets approved in USA) led to a 5-6 fold increase of alendronate’s bioavailability 166 
resulting in bioinequivalence [40]. Drug permeability can be affected or not by the presence of excipients as revealed by in vitro 167 
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permeability studies (Caco-2 models). The presence of lactose, HPMC and PEG did not alter the permeability of BCS Class III 168 
compounds [41]. A drug dependent excipient effect has been shown in the case of Tween 80 due to its P- glycoprotein (P-gp) 169 
inhibitory effect, as it increases the apparent permeability (Papp) of drugs that are P-gp substrates (e.g. cimetidine) while other drugs 170 
remain unaffected (e.g. atenolol, acyclovir) [42]. Sodium Lauryl Sulfate (SLS) shows a concentration-dependent effect on the 171 
permeation of low permeability drugs with an increase in the Papp when present in low concentrations (0.139 mM) [42] while at 172 
increased concentrations drug permeation is even greater due to excipient-mediated disruption of the cell monolayer [41, 42]. The in 173 
vivo impact of excipients on drug permeability has to be further investigated, as in vitro permeation models (such as Caco-2 174 
monolayers) are more sensitive in excipient effects and may overestimate their impact [41]. Generalized conclusions should be 175 
avoided without prior scientific knowledge on the biopharmaceutical aspects of excipients. Although, there is a tendency to investigate 176 
the effect of excipients with a prominent role on dissolution and bioavailability (surfactants, carriers, bioadhesives, polymers, 177 
copolymers etc.), the intended product performance can be compromised even from excipients whose initial role is not related to drug 178 
release/dissolution [40]. 179 
4.2 Effect of physiological conditions on excipients 180 
When formulating a solid dosage form, the varying composition and heterogeneity of the gastrointestinal tract need to be 181 
considered. Factors such as properties of the gastrointestinal contents (i.e. pH, ionic strength, temperature, viscosity, bile salts 182 
concentration) and gastrointestinal motility will have an impact on drug release. Gastric emptying will influence drug, excipient and 183 
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product characteristics. Moving from the acidic stomach to the more basic small intestine affects the ionization and solubility of weak 184 
acidic/basic drugs and subsequently their absorption. Moreover, the changes in physiological conditions by the presence of meal (fed 185 
state) can alter solid dosage form performance. Excipient properties and their functionality will be impacted by this heterogeneous 186 
environment (data indicating the effect of physiological conditions on excipient functionality is discussed in detail in the next sections 187 
of this review). Excipient variability should be addressed in a biorelevant perspective reflected in in vitro dissolution testing. The use 188 
of biorelevant media mimicking physiological gastrointestinal aspects in fasted and fed state (i.e. bile secretion, meal components, 189 
surface tension, osmolality) [43, 44] could enable the investigation of the gastrointestinal effect on excipient functionality and drug 190 
release. A better understanding of the complex excipient effects taking place in the gastrointestinal tract and their impact in product 191 
performance could be achieved by the combination of biorelevant in vitro dissolution testing with imaging techniques, where 192 
applicable [45]. 193 
5. Excipients in solid dosage forms 194 
Particle size distribution, pore size distribution and surface area are critical properties for dissolution of solid dosage forms 195 
[13], but not the sole ones. In the following sections material properties of commonly used excipients in solid dosage forms are 196 
discussed, revealing their functional role on drug product performance. Excipients are categorized according to their function in solid 197 
dosage forms (Table 1) and cases related to their functionality or variability are reviewed. 198 
5.1 Diluents 199 
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Diluents, referred also as fillers, are incorporated into solid dosage forms to adjust their mass. When low drug doses are required, 200 
fillers may comprise up to 90% of the total dosage weight to ensure adequate product processability throughout manufacturing. 201 
Despite the simplicity of their role, their high concentrations may render them high risk factors for product performance. Their 202 
physical and chemical properties are significant attributes for their functionality and may trigger dosage variability, but their impact is 203 
usually related to other product components. Diluents can be either inorganic or organic materials. Typically used diluents include: 204 
lactose, mannitol, microcrystalline cellulose and dicalcium phosphate [46]. 205 
5.1.1 Lactose 206 
Lactose is a disaccharide consisted of D-galactose and D-glucose units linked through a β (1-4) glycosidic bond and is produced 207 
from bovine milk. Lactose is mainly used as soluble diluent in formulations, but it possesses binding properties as well[47]. 208 
Molecular Properties 209 
Two anomeric forms of lactose, referred as α and β, are present, according to glucose stereochemistry. An interchange between the 210 
two isomers, called mutarotation, is observed in aqueous solution. When in equilibrium (0-100°C), the ratio between the two forms is 211 
approximately 60:40 for β and α lactose, respectively. They differ in physical properties such as melting point, density, specific optical 212 
rotation, and on solubility with β lactose being more soluble in water (20°C; 0.5 g/mL) than the α anomer (0.075 g/mL) [48]. The α 213 
isomer, according to temperature, may exist as monohydrate (<120°C) or anhydrous (>120°C) form, while β lactose is anhydrous [48]. 214 
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These molecular differences affect lactose’s solid state properties and products with varying attributes are available on the market. 215 
Presence of impurities in lactose brands may catalyze drug hydrolysis, affecting drug stability [49]. 216 
Structural Properties 217 
Varying crystallization patterns are observed due to the presence of the two anomers and their solubility difference. The α isomer 218 
crystallizes as a monohydrate in low temperatures (<93 °C) in a variety of shapes (prism, pyramidal, tomahawk)[47]. Uneven-219 
diamond shape crystals of 80% β-lactose anhydrous with a small portion of α-lactose anhydrous are formed with increased 220 
temperature (>93 °C) [48]. Spray-dried lactose, consisted of α-lactose monohydrate and amorphous lactose, in a spherical shape with 221 
excellent flow properties has also been produced. The structural differences lead to products with varying compactions forces [19]. 222 
Higher initial solubility and dissolution rate for the β-form was observed from different crystalline lactose powders in water at 37 °C, 223 
followed by a decrease in the order β-lactose (0.5 g/mL water) >α-lactose anhydrous (0.27 g/mL water) >α-lactose monohydrate (0.13 224 
g/mL water) but due to mutarotation, final solubility for all lactose types was the same [47, 50]. Monohydrate α and β lactose 225 
disintegrated faster compared to anhydrous lactose and an increase in compression force resulted in increased disintegration time. The 226 
fast disintegration was attributed to the increased porosity of lactose tablets which allowed quick water penetration [50]. 227 
Particle Properties 228 
Particle size distribution of lactose is not specified in pharmacopeias. Lactose brands with varying size distribution are 229 
available in the market[47] . When the effect of lactose particle size in product manufacturing was studied, it was shown that in direct 230 
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compression, an increase in lactose particle size will enhance blend flowability and form weaker tablets [51], due to decreased 231 
cohesiveness of particles. Studies on wet granulation behaviour of lactose linked particle size and size distribution to granule porosity. 232 
Small particle sizes (53 µm) give granules with higher porosity, as a result of the higher resistance of small particles to densification 233 
[52]. Narrow ranges of particle size (40-75 μm, 212-250 μm) produced granules of higher porosity due to the absence of fine particles 234 
that tend to occupy void volumes between larger particles [52]. As porosity is considered an important parameter for water 235 
penetration, particle properties of lactose can have a major impact on dissolution. 236 
Level 237 
Lactose may greatly enhance dissolution of poorly soluble drugs as the soluble diluent improves powder and tablet wettability. Studies 238 
on ethinamate capsules showed a decrease in drug release when 10% w/w lactose was used in the formulation but improved 239 
dissolution when diluent concentrations reached levels of 50% w/w [53]. Increasing the percentage of fine lactose in indomethacin 240 
formulations (interactive mixture of API and coarse lactose) resulted in improvement of the drug’s dissolution rate, as rapid 241 
dissolution of lactose leaving open structures enables deagglomeration of indomethacin particles [54]. For a soluble drug 242 
(chloramphenicol) inclusion of lactose at 50% w/w in the capsule formulation had no effect on drug’s dissolution. Increasing lactose 243 
to a level of 80% w/w slowed down chloramphenicol dissolution, as the dissolved diluent retards drug release [55]. The interplay 244 
between lactose content and drug’s BCS class was recently portrayed in a top-down approach comparing marketed innovator and 245 
generic products with proved bioequivalence. For BCS class I and class III drugs relatively large differences in lactose level were 246 
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observed whereas for BCS class II and class IV drugs small variations in these levels were noted. The probability of bioinequivalence 247 
based on these differences in lactose levels between the innovator and generic products was classified as low or BCS class I drugs, 248 
medium for BCS class II and III drugs and high for BCS class IV drugs [56]. 249 
Biopharmaceutical Properties 250 
Lactose can affect bioavailability through a dissolution modification effect. No impact on other physiological factors has been 251 
reported [56]. Interactions between milk proteins and lactose have been described. Low lactose concentrations decreased the viscosity 252 
of the milk dispersion (lactose assembles around protein molecules) whereas high lactose concentrations increased the viscosity of the 253 
dispersion (reduction in water-protein interactions) [57]. The potential interplay of meal intake and lactose on physiological factors 254 
and drug release and dissolution has not yet been investigated in a biopharmaceutical perspective. 255 
5.1.2 Dicalcium Phosphate 256 
Calcium phosphate dibasic, or dicalcium phosphate (DP), is an inorganic insoluble diluent used in tablet and capsule manufacturing. 257 
Molecular and Structural Properties 258 
Two hydration forms of dicalcium phosphate, anhydrous (DPA) and dihydrate (DPD), are used in pharmaceutical development[58, 259 
59]. The anhydrous form occurs as a triclinic crystal while the dihydrate forms a monoclinic structure[58, 59]. Dicalcium phosphate 260 
dihydrate presents good flow properties and low hygroscopicity. According to temperature (40-50 °C) and humidity (32-75% relative 261 
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humidity) [60], though, it tends to lose water of hydration that may cause chemical instability of APIs in dosage forms [61]. The 262 
anhydrous form presents an alternative without compromising drug stability. The two forms differ in porosity, as a result of their 263 
different hydration. The anhydrous form exhibits higher porosity due to the absence of water in the crystal structure, leading to its 264 
better compressibility and faster disintegration [62]. 265 
Level 266 
As for lactose, the effect of dicalcium phosphate on drug release is profound in high levels of the diluent. Replacing lactose with 267 
dicalcium phosphate dihydrate or anhydrous resulted in decreased and extended release of alprazolam from matrix tablets containing 268 
HPMC as well. In binary systems containing different ratios of lactose and dicalcium phosphate dihydrate, increasing the amount of 269 
the insoluble diluent did not impact dissolution rate, and only when, dicalcium phosphate dihydrate was the sole diluent and in high 270 
level (36.5% w/w) drug dissolution was affected [63]. 271 
Biopharmaceutical Properties 272 
The pH difference of the stomach and intestinal contents is expected to affect dicalcium phosphate’s behavior[64], due to its 273 
higher solubility in acidic media. In a comparative study on the effect of pH on superdisintegrant functionality (discussed in sections 274 
5.4.1, 5.4.2, 5.4.3), the influence of different types of diluents on drug dissolution was evaluated. Swelling capacity of some 275 
disintegrants is lower in acidic medium, leading to reduced disintegration and dissolution. When lactose was the diluent, the reduced 276 
swelling of superdisintegrants caused a decrease in the dissolution of hydrochlorothiazide (HCTZ) tablets in acidic medium (0.1 N 277 
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HCl, pH=1; paddle method, 50 rpm, 37 °C). Substituting lactose to DPD led to higher drug release in the acidic solution, compared to 278 
water and the effect of superdisintegrant swelling to reduce dissolution in acidic media was not observed (Figure 2) [65]. Although the 279 
overall dissolution rate of HCTZ was higher in tablets containing lactose compared to DPD tablets (even in the acidic medium), this 280 
example demonstrates the complex interactions between formulation components and their potential to alter dissolution behavior in 281 
the different gastrointestinal compartments. 282 
5.2 Binders 283 
Binders are typically used in solid dosage form manufacturing to promote adequate mechanical strength of granules or tablets. Wet 284 
binders are used in wet granulation to ensure appropriate granule formation with good flow properties while dry binders are 285 
incorporated after the granulation step or in direct compression to facilitate compaction and formation of strong tablets. Commonly 286 
used binders include: disaccharides, starches, celluloses and synthetic polymers (polyvinylpyrrolidone, polyethylene glycol). 287 
5.2.1 Microcrystalline Cellulose 288 
Cellulose is a polysaccharide composed by β (1→4) linked D-glucose units forming microfibrils in plant cells (Figure 3). These 289 
microfibrils bond together to create large crystalline regions with intervened amorphous parts. Microcrystalline cellulose (MCC) is 290 
obtained by hydrolytic depolymerisation of cellulose in order to isolate the crystalline regions with, usually, a subsequent spray drying 291 
step to obtain dry and porous particles[66]. Cellulose for MCC production is mainly derived from wood. Different grades of MCC 292 
with a variety of particle size/particle size distribution, moisture content and bulk density are available in the market. 293 
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MCC is mainly used as a binder/filler in tablet manufacturing, with good disintegrant and lubricant properties. It’s functionality as 294 
a binder relates to its ability to deform when compression force is applied. MCC particles come in closer contact and form multiple 295 
hydrogen bonds leading to strong compacts. Potential critical material properties of MCC with respect to its functionality as a binder 296 
include: moisture content, particle size, bulk density, specific surface area, degree of polymerization and crystallinity [4]. 297 
Molecular Properties 298 
The degree of polymerization may affect tabletability, with highly polymerized MCC molecules leading to powders with small 299 
particle size and smooth surface. These attributes impact flowability (finer fibers with increased adhesiveness) but have a positive 300 
effect on tablet hardness. Tablets containing MCC with a degree of polymerization of 244 and 299 were twice as strong as those 301 
produced with an MCC with a degree of polymerization of 199 [67]. In general, degrees of polymerization favoring the fibrous 302 
structure of the polymer, improve tabletability but compromise powder flowability [4]. Impurities in MCC brands can affect drug 303 
stability (hydrolysis, drug adsorption onto the polymer) [49]. 304 
Structural Properties 305 
Two MCC polymorphs, MCC I and MCC II, differing on the hydrogen bonding between the microfibrils (parallel and anti-306 
parallel orientation of the MCC chain, respectively) have been described. Powder properties of the two polymorphs show great 307 
variation and a twofold difference of the swelling value of the two polymorphs is observed (0.2 mL/g for MCC I vs 0.8 mL/g for MCC 308 
II) leading to rapid disintegration of MCC II due to the higher water uptake [68]. The degree of crystallinity/amorphicity has a similar 309 
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pattern, and the presence of amorphous regions in MCC affects water penetration that could affect tablet dissolution. MCC undergoing 310 
an extra grinding step to reduce crystallinity and generate amorphous structures led to an increase in water penetration owned to 311 
hydrogen bonding between the amorphous regions and water [69]. MCC crystallinity has an impact on dissolution, as an increase in 312 
water penetration is noted with lower MCC crystallinity. A decrease of the dissolution rate of acetaminophen tablet as MCC 313 
crystallinity decreased from 65.5% to 37.6% and subsequent increase of the dissolution rate as the degree of MCC crystallinity was 314 
further reduced (25.8% to 12.1%) has been reported [70]. These studies suggest that the crystallinity of MCC could be a critical 315 
material attribute that should be examined with respect to dissolution. 316 
Particle Properties 317 
Particle properties impact tablet hardness and dissolution. A decrease in particle size of MCC would increase cohesiveness 318 
resulting in production of stronger tablets after compression. A 32 μm decrease in MCC particle size (d50) showed a statistically 319 
significant increase in disintegration time of tablets containing otanabant (BCS Class IV drug), spray dried lactose and magnesium 320 
stearate [51]. Porosity affects disintegration/dissolution, with water penetration in plain MCC tablets of 15% nominal porosity to be 321 
achieved in 19 s compared to 148 s needed for 5% porosity tablets [71]. 322 
Level 323 
When MCC is incorporated into solid dosage forms as a binder/diluent, it typically comprises the 20-90% w/w of the tablet 324 
[66]. High MCC concentrations, may greatly increase tablet hardness leading to problematic disintegration and dissolution. For this 325 
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reason when microcrystalline cellulose is used as a binder, inclusion of a disintegrant is recommended to achieve adequate 326 
disintegration and dissolution. As a polymer, MCC tends to swell in aqueous solution, with swelling values of 0.2 mL/g and 0.8 mL/g 327 
for MCC I and MCC II, respectively [68]. In high MCC concentrations, the increased viscous layer, caused by swelling, will 328 
potentially affect drug release. 329 
Biopharmaceutical Properties 330 
Changing the temperature of the dissolution medium affects MCC functionality. Increasing the temperature of the dissolution 331 
medium (water; from 20 °C to 37 °C) resulted in faster swelling and water transport in plain MCC tablets, even though, full 332 
disintegration did not occurred throughout the duration of the experiment at both temperatures [71]. Information related to other 333 
biopharmaceutical properties of MCC have not been reported. 334 
5.2.2 Hypromellose 335 
Hypromellose, also called hydroxylpropyl methylcellulose (HPMC), is a water soluble nonionic cellulosic polymer substituted 336 
with methoxy and hydroxypropyl groups (Figure 4). HPMC is manufactured by chemical modification of cotton or wood derived 337 
cellulose. It is used as a wet granulation or dry binder and as a rate controlling release polymer in extended release formulations[72] 338 
[72]. The effectiveness of HPMC as a release modifier is advantageous in reducing dosage frequency and sustaining drug blood levels. 339 
But it can compromise drug dissolution when used as a binder, where controlled release is not necessary expected, as upon contact 340 
with aqueous solutions, the polymer hydrates and forms a viscous gel layer which is thickened when more water penetrates. As the 341 
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polymer becomes fully hydrated, it tends to relax and dissolve, in a process called erosion [73]. Drug release when HPMC forms this 342 
viscous layer consists of three processes: dissolution in the matrix, diffusion through the gel layer and delivery of the drug in the 343 
medium as the polymer erodes [74]. Different grades of HPMC are available in the market according to particle size distribution, 344 
viscosity and methoxy:hydroxypropoxyl substitution. These characteristics of HPMC along with its particle size affect the 345 
functionality of the excipient. 346 
Molecular Properties 347 
The degree of polymerization and substitution are critical aspects for HPMC performance. Molecular weight and chain length 348 
have a direct effect on the viscosity of HPMC aqueous solutions. H-bonding between oxygen atoms in ether groups and water 349 
molecules leads to extension of the polymer and formation of a coiled shaped structure. Coiled polymers tend to form more H-bonds, 350 
entrap water and form entanglements with other coiled molecules resulting in increased resistance to flow. Therefore, polymers with 351 
high molecular weight tend to swell faster and form viscous layers. The gel layer thickness increases with increased molecular weight 352 
while erosion of the layer is decreased [75]. A counter effect of HPMC molecular weight on gel formation has been reported. 353 
Increased molecular weight results in improved swelling properties but reduces water penetration, as the high number of 354 
entanglements lead to a less porous layer [76]. Since water penetration affects drug release and dissolution, HPMC molecular weight 355 
could be considered as a critical material property whose variation impacts release and dissolution. When three differently substituted 356 
HPMC grades were used in acetazolamide (poorly soluble drug) tablet (HPMC 2910, HMPC 2208, HPMC 2906; the first two digits 357 
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indicate the % methoxy groups and the two last digits the % of hydroxypropyl group) a decrease in drug release was found with a rank 358 
order HPMC 2910> HPMC 2208> HPMC 2906 [77]. Not only the hydroxypropyl content and the degree of substitution but also the 359 
substitution pattern affects release and dissolution. Heterogeneity in substitution pattern alters the release of the polymer due to 360 
hydrophobic interactions between the substituents [78] with an expected subsequent drug release alteration [79]. Variation in 361 
substitution pattern causes batch to batch variability and sourcing from different suppliers should be evaluated [80]. 362 
Particle Properties 363 
Particle size affects drug release and dissolution through its impact on tablet hardness and water penetration. HPMC of small 364 
particle size form stronger tablets due to increased surface area and interparticle cohesiveness, whereas HPMC of larger particles 365 
trigger rapid dissolution, as they do not fully occupy space around particles leaving voids for water penetration [81]. HPMC particle 366 
sizes above 113 μm increased dissolution rate of aspirin [82]. Drug release was caused by: disintegration for large particle sizes, 367 
diffusion for medium sizes and a combination of diffusion and erosion for smaller particle sizes. These effects were attributed to the 368 
proximity of polymer particles and the differences in the porosity of the formed hydrogel [82]. 369 
Level 370 
The impact of HPMC properties on dissolution depends on the amount of HPMC in the formulation. When used as a binder, 371 
HPMC is added in a level of 2-5% w/w [72]. Direct impact of HPMC concentrations on dissolution has been reported for levels >10 % 372 
w/w [83]. The level of the polymer makes solid formulations more prone to particle size variation. The faster dissolution observed 373 
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with higher HPMC particle sizes due to their porous arrangement [81], is annihilated in high concentrations as more polymer chains 374 
are present leaving no spaces for water penetration [81]. 375 
Biopharmaceutical properties 376 
From a biopharmaceutical perspective, ionic strength, composition of dissolution medium and presence of food are likely to affect 377 
HPMC performance. The presence of salts in the medium affect the hydration of the polymer. Some salts, cause polymer dehydration 378 
dependent on salt’s affinity to water of hydration (salting-in/salting-out effect) and subsequent loss of gel uniformity leading to 379 
inconsistent drug release [84]. NaCl interacts with water and affects the sol-gel formation (thermo-reversible gelation of aqueous 380 
polymeric solutions) of HPMC [85]. In an aqueous HPMC solution, the hydroxyl groups of the polymer interact with water through 381 
hydrogen bonding. Upon heating, these bonds are disrupted leaving the hydrophobic parts of the polymer exposed to interact with 382 
each other with subsequent formation of a gel. Increasing NaCl concentrations (0-0.8 M), as salting out ion, shifts this thermogelation 383 
to lower temperatures [85]. Presence of salts in high concentrations will affect gel layer formation and can lead to burst drug release 384 
[86]. Low salt concentrations impede polymer erosion, which is more pronounced in low viscosity grade polymers·[87], leading to 385 
decreased drug dissolution. Implications caused by the heterogeneity in the gastrointestinal physiological conditions {gastric (35mM 386 
NaCl) and intestinal contents (100 mM NaCl) and fasted and fed state conditions [88]} are expected. 387 
The behavior of cellulosic polymer can be strongly related to physiological temperature. In an intersupplier comparison of HPC 388 
batches, differences in dissolution rate of HCTZ tablets were reported and attributed to HPC solubility and its cloud point. The cloud 389 
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point, that is the temperature above which a polymer solution becomes turbid, relates to polymer’s hydrophilicity with less hydrophilic 390 
polymers undergoing this transition in lower temperatures, and a less viscous layer is formed in temperatures above it. Therefore, 391 
when the HPC brand with a cloud point closer to 37°C was used,  faster dissolution of HCTZ from the tablet formulation was 392 
observed [89]. Since HPC and HPMC are included in the same polymeric class possessing comparable functionality and properties, a 393 
similar behavior is expected for HPMC. 394 
Meal components, such as sugars and fat, interact with HPMC affecting its biopharmaceutical properties. The same ionic effect on 395 
HPMC dehydration pattern, has been found for dietary sugars. Dietary sugars cause dehydration of the polymer according to their 396 
structure and lactose is one of the most potent disaccharides in inducing HPMC dehydration even in low concentration (0.5 M) [90]. 397 
In low sugar concentrations, the decreased erosion leads to thicker gel layers that delay drug diffusion and release on the medium, 398 
whereas in higher concentrations, the suppression of the gel formation leads to rapid drug release [90]. The presence of milk reduced 399 
caffeine release from tablets containing HPMC. High fat concentrations, relevant to fat content of the medium, were deposited on 400 
these tablets at the early stages of gel formation, and the fat layer was still present at later time points. Possible coalescence between 401 
fat droplets and phase separation of these lipidic compositions on the formed gel resulted in reduced drug release [91] [92] 402 
Furthermore, hydrodynamics of the dissolution apparatus permitted a better understanding of the effect of milk on the release from 403 
these tablets containing HPMC. With the flow through cell apparatus the decrease in dissolution rate is more pronounced due to the 404 
absence of erosional forces and occurs in lower fat contents than in the basket apparatus [91]. These findings suggest that the fed state 405 
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affects the release from formulations containing HPMC. Biorelevant dissolution testing could shed light on the complex effect of 406 
physiological conditions on excipient functionality and release/dissolution. 407 
Dissolution of low and high viscosity grade HPMC in phosphate buffer pH 6.8 studied with surface dissolution UV-imaging 408 
revealed that for both grades the gel layer was formed rapidly within 15 minutes. For the low viscosity polymer, the initial high 409 
concentrations decreased as the polymer expanded. Then, the gel layer was stabilized from the dissolution of undissolved particles 410 
(that contribute to the increased polymer concentrations in close proximity to the sample). As the polymer expanded, its concentration 411 
was decreased due to polymer disentanglement forming the diffusion layer and the polymer was completely dissolved and diffused in 412 
the bulk (Figure 5a). HPMC of higher viscosity showed increased concentrations in the gel layer but decreased rate of diffusion and 413 
dissolution (Figure 5c). When agitation was applied, a thinner layer with lower HPMC concentrations and slow diffusion rate were 414 
observed (Figure 5b). The effect of agitation was more pronounced for the low viscosity HPMC, as it was more sensitive to shear 415 
force (Figure 5d) [74]. 416 
5.3 Lubricants 417 
Lubricants are used in solid dosage forms manufacture to enhance processability of intermediate blends and tablets. Friction or 418 
cohesiveness between particles impose a barrier in powder or tablet flowability affecting content uniformity, compaction, tablet 419 
hardness and therefore product performance. Lubricants address flowability issues, by adherence to die or particle surfaces and 420 
reduction of friction or cohesiveness leading to adequate flow properties. Lubrication involves the creation of a film between surfaces 421 
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or interfaces in order to reduce cohesion between particles or adhesion of particles onto surfaces [93]. The most commonly used 422 
lubricants include stearates (magnesium, calcium, sodium), talc, waxes and sodium lauryl sulfate. Magnesium stearate properties and 423 
behavior are reviewed as it possesses excellent lubricant properties. 424 
5.3.1 Magnesium Stearate 425 
Magnesium Stearate, a salt containing two equivalents of a fatty acid (usually stearic and palmitic acid) and a charged magnesium, 426 
is manufactured by a reaction between fatty acid salts and inorganic salts (Figure 6) [94]. Fatty acids can be bovine or vegetable-427 
derived [95]. Its lubricant effect relates to the adherence of the polar moiety on granules or powders while the lipophilic part is 428 
oriented away from the particle’s surface [96]. Its ability to form a waxy layer around particles and tablets leads to reduced water 429 
penetration and dissolution can be compromised due to its hydrophobicity. Lubrication efficiency and dissolution, are inversely related 430 
as over-lubrication decreases dissolution rate.  431 
Molecular Properties 432 
A maximum of 4-5% in magnesium weight fraction and a minimum of 40% in stearic acid weight fraction is described in the 433 
USP [97]. Magnesium stearate is a mixture of stearic and palmitic salts. The sum of stearic and palmitic acid should encounter for the 434 
90% of total weight fraction [98], but the exact ratio of the stearic (C-18) and palmitic (C-16) acid, composing the commercial 435 
magnesium stearate, is not set in the Pharmacopoeia specifications.  436 
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Depending on the manufacturing process and humidity, four different hydrates of magnesium stearate can be formed 437 
(anhydrate, monohydrate, dihydrate, trihydrate), leading to different crystal habits with altered functionality [99]. When preparing 438 
magnesium stearate with a precipitation method, precipitation in pH 9 leads to the formation of the dihydrate form, while precipitation 439 
in pH 7 or 11 leads to a lower hydration state [100]. 440 
Structural Properties 441 
The different crystal structures identified for the different magnesium stearate hydrates include the plate-shaped structure for 442 
the dihydrate and needle-shaped structure for the monohydrate and trihydrate form [100-102]. This difference in shape is attributed to 443 
a change in the angle of inclination of the hydrocarbon chain caused by the addition of the water molecule [100]. The different 444 
crystalline forms have an effect on the magnesium stearate functionality as an excipient. The monohydrate form produces tablets with 445 
lower variability during tablet manufacturing [99].The dihydrate form acts as better lubricant due to its lamellar shape as it shears 446 
readily under applied tangential forces [101, 103, 104] and has a lower tendency to cause over-lubrication [99]. The irregularity of 447 
commercial magnesium stearate shape, compared to high purity magnesium stearate and palmitate, relates to reduced lubricant 448 
properties [104]. 449 
Particle Properties 450 
Surface area (SA) and particle size affect magnesium stearate functionality. Increasing the SA of the lubricant (due to particle 451 
size reduction) leads to higher adhesion work and a thin homogeneous layer on particle surface, whereas decreasing SA results in 452 
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enrichment of the surface with lubricant particles [96]. Larger particles have less tendency to strongly adhere to particle surfaces 453 
leading to less uniform coats. In both cases, (strong or thick layer) water will face difficulties in penetrating this layer. The high 454 
coverage of particle surfaces with the lubricant during blending reduces interparticle bonding leading to weakened tablets [105]. 455 
Investigation of the optimum particle size/SA of magnesium stearate, without compromising any quality attributes, is needed as the 456 
two extreme levels both may have a negative impact on drug release.  457 
Level 458 
Since magnesium stearate is hydrophobic and care should be taken when added in solid dosage forms as it can compromise drug 459 
release. The amount and the mixing time of magnesium stearate in the formulation are critical dissolution variables; increased levels 460 
and longer mixing time reduces drug dissolution from capsules [94]. A range of 0.25-5.0% w/w magnesium stearate is used in drug 461 
product development [94]. Increasing magnesium stearate level (0.25%-1.0%-5.0% w/w) decreased indomethacin dissolution, due to 462 
the decreased interfacial area between the dissolution medium (acetate buffer pH 5 with 0.1% w/v sodium lauryl sulphate) and the 463 
drug [106]. Mechanofusion, a process used to coat particles with fine materials, has been found beneficial for drug dissolution, as 464 
coated particles with magnesium stearate exhibited decreased agglomeration and enhanced dissolution [107]. In the case of 465 
mechanofused magnesium stearate-coated indomethacin powder, drug dissolution was enhanced only in the early stages of 466 
dissolution, and dissolution reached a plateau (~80% drug dissolved) at later stages) with slightly higher concentrations achieved only 467 
for the 0.25 and 1% w/w magnesium stearate [106]. 468 
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5.4 Superdisintegrants 469 
Disintegration is needed in immediate release dosage forms where quick onset of action is desired. A single or a combination 470 
of mechanisms have been proposed for the disintegration of solid formulations. Firstly, swelling of the disintegrant can compensate 471 
the adhesion forces of other formulation components, causing the tablet fragmentation. Furthermore, the porous structure of several 472 
disintegrants and their ability to adsorb water via capillary action (wicking) is a potential mechanism for their action. Finally, 473 
fragmentation of tablets can be caused from elastic deformation of disintegrants under pressure and release of high energy upon 474 
exposure to water due to the ability of particles to recover their initial structure [108]. Common disintegrants used in solid 475 
formulations include: starches, modified starches. The introduction of low concentrations of superdisintegrants as agents providing 476 
disintegration within few minutes is optimistic in terms of drug delivery in enhancing the dissolution rate of solid formulations [109]. 477 
The most notable superdisintegrants include crosslinked polymers such as: sodium starch glycolate (SSG), croscarmellose sodium 478 
(CCS) and crospovidone. 479 
5.4.1 Sodium Starch Glycolate 480 
Starch is a polysaccharide consisted of amylose and amylopectin, and can be extracted and processed for pharmaceutical use 481 
by several plants including maize, potato, rice, corn. Starch modification can be performed in order to improve its functionality as 482 
disintegrant. SSG is the sodium salt of the carboxymethyl ether of starch (Figure 7). SSG derives from starch (from several sources) 483 
after two chemical modification processes: substitution to increase hydrophilicity and cross-linking to reduce solubility and gel 484 
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formation upon contact with water [110]. It is used in pharmaceutical manufacturing as a superdisintegrant as it acts through rapid 485 
swelling due to the adsorption of large amounts of water leading to fast disintegration [111]. The functional mechanism of SSG was 486 
revealed by High-Resolution Real-Time Magnetic Resonance Imaging (MRI) through investigation of the direction to which the tablet 487 
expands when disintegration occurs. SSG acts through swelling as an omni-directional expansion was observed with different grades 488 
of SSG [112]. Different grades of SSG are available according to particle size distribution, sodium chloride content and pH. 489 
Molecular Properties 490 
The degree of substitution, due to the role of the carboxymethyl group on functionality, has to be defined. In USP, the amount 491 
of sodium in SSG is set between 2.8-4.2%, whereas the degree of substitution is not specified [113]. Values for the degree of 492 
substitution between 0.23-0.32 have been reported [114]. Hydration and swelling of SSG leading to fast tablet disintegration, relate to 493 
degree of substitution. An increase in swelling and water uptake observed as substitution increases from 0.20 to 0.29 and the opposite 494 
effects at higher substitution. An optimum degree of substitution value between 0.28-0.29 for faster and higher dissolution of aspirin 495 
tablets was reported [115]. A higher degree of substitution can lead to increased drug-excipient interactions as weakly basic drugs can 496 
be adsorbed onto the polymer [49] Crosslinking in SSG, achieved through the phosphate group, leads to a high spacing between SSG 497 
chains facilitates water penetration and swelling and reduce gel formation [109]. The extended swelling of SSG compared to other 498 
swelling disintegrants is attributed to this type of crosslinking (e.g. croscarmellose is crosslinked through esterification which does not 499 
allow this high spacing between the polymer chains). An increase of 25%-35% of crosslinking, leads to powders with increased 500 
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swelling and water uptake with further increase in crosslinking leading to lower swelling and water uptake. An optimum value at 501 
medium levels of crosslinking (33-35%) for dissolution of aspirin tablets has been reported [115].  502 
Particle Properties 503 
Particle size affects disintegrant functionality of SSG, with larger particles being more efficient [110]. An approximate 504 
threefold increase in particle size of SSG resulted in a proportional decrease in disintegration time [116].It can be speculated though 505 
that in the case of super-disintegrants, it is questionable whether a change in the second disintegration time-scale can have a direct 506 
major impact on dissolution. An indirect effect of the particle size on dissolution is more likely to be expected through its effect on 507 
solution’s viscosity. As the particle size of polymers decreases, a more viscous layer is formed due to increased interaction with water, 508 
creating a barrier for drug diffusion and leading to delayed dissolution 509 
Level 510 
Typical amount of SSG used in drug formulation ranges between 2%-8% w/w [117]. Low SSG levels (0.25%, 0.5% and 1% 511 
w/w) in paracetamol tablets resulted in long and varied disintegration times (60min, 40min, 2-15 min, respectively), whereas at higher 512 
SSG levels (2% and 4% w/w) the disintegration time was consistent within one minute [115]. SSG in higher levels (>8% of tablet 513 
weight) causes an increase in disintegration time due to the formation of a viscous layer which hinders water penetration in the 514 
formulation, irrespective of the API solubility [111]. 515 
Biopharmaceutical Properties 516 
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The pH of the medium affects SSG functionality[65]. SSG hydrates as the anionic carboxyl group interacts with water[65]. In 517 
low pH, the polymer gains its neutral form and a less extended interaction with water is expected.[65] In simulated gastric media (0.1 518 
N HCl, pH=1) an approximate twofold reduction in the swelling value and the water uptake of SSG was observed compared to the 519 
values in intestinal media (phosphate buffer, pH=6.8) (Figure 8). Compacts of SSG with spironolactone, filler and lubricant did not 520 
show the this variation in water sorption in the two media, a fact attributed to the crystallinity of the polymer and the reduced water 521 
accessibility when particles are consolidated in strong compacts [109]. 522 
5.4.2 Croscarmellose sodium 523 
CCS is a cross-linked polymer of carboxy methylcellulose. Wood or cotton-derived cellulose reacts with sodium hydroxide and 524 
sodium monochloroacetate to produce the carboxyl methyl cellulose in a degree of substitution of 0.7. The excess of 525 
monochloroacetate hydrolyzes to glycolic acid which reacts with the sodium carboxy methyl group of the polymer and catalyzes the 526 
esterification of this group with the closest polymer chains leading to the formation of crosslinks (Figure 9)[118]. It is used in tablet or 527 
capsule manufacturing as a super disintegrant acting mainly through a combination of swelling and wicking. The swelling mechanism 528 
of CCS was confirmed by MRI studies, as tablets containing CCS expanded in an omni-directional way [112]. At initial stages, 529 
disintegration depended on tablet density and water penetration was reduced as tablet hardness was increased. At later stages, as the 530 
polymer swells, new pores were formed and water uptake was no longer related to tablet density. Stronger solid dosage forms resulted 531 
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in better disintegration, as their less porous structure caused a greater swelling force to be exerted on tablets and formation of widen 532 
pores that facilitate water penetration [112]. 533 
Molecular Properties 534 
As swelling of CCS is attributed to the hydration of the carboxy methyl group, the degree of substitution defines CCS 535 
functionality. Degree of substitution refers to the total acidic (acid form) and basic (sodium salt) components of superdisintegrants. 536 
The basic substituent (level of salt) correlates CCS disintegration to the pH of the medium, as CCS turns to its acidic form on low pH 537 
with a subsequent loss of its swelling ability [119]. Measuring the volume median diameter gave higher values for CCS in water 538 
compared to HCl 0.1 N [65], indicating a more efficient swelling of the sodium salt than the free acid due to higher hydrophilicity. 539 
Acid/base ratio and total degree of substitution vary along different CCS brands. Brands with higher basic substituents exhibit larger 540 
settling volumes and higher maximal water uptake and size increase. Variation in disintegration times can be attributed to differences 541 
in composition when all other properties, such as particle size are similar [119]. A higher degree of substitution may induce drug-542 
excipient interactions. Exposure of delavirdine mesylate tablets containing CCS to high humidity (40 °C, 75% RH) for 8 weeks led to 543 
a decrease in drug’s dissolution probably from the conversion of delavirdine to its free basic form due to an interaction between the 544 
carboxyl group of the polymer and methanosulfonic acid [120]. 545 
Particle Properties 546 
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For croscarmellose, as a swelling polymer, a larger particle size is expected to lead to enhanced swelling and fast 547 
disintegration. Brands of higher particle size of different croscarmellose suppliers showed increased settling volumes and water uptake 548 
[119]. An optimum particle size has not been reported. Since, croscarmellose forms a viscous layer upon contact with water, it should 549 
be expected that the notion that smaller particles sizes will form a more viscous layer due to enhanced interactions with water would 550 
be applicable 551 
Level 552 
In tablet formulations, CCS is used at 0.5%-5.0% w/w to promote fast disintegration[118]. As CCS swells upon contact with 553 
water, an increase in its fraction results in the formation of a viscous gel layer acting as a barrier for product disintegration. For 554 
aspirin, ascorbic acid and ibuprofen tablets, an optimal superdisintegrant concentration of 7% of the tablet weight was reported to give 555 
best disintegration values and up to this level, disintegration time increased irrespective of drug solubility[111]. Even if the difference 556 
in disintegration time is low, dissolution can be greatly affected as the drug will have to diffuse through the viscous disintegrant layer. 557 
Biopharmaceutical Properties 558 
Since CCS is a sodium salt, the pH of the medium affects its ionization. In acidic medium, CCS turns to its neutral form with 559 
decreased hydrating and swelling capacity[65], but to lesser extent than the highly swelling SSG (section 5.4.1.) (Figure 8) [109]. 560 
Therefore, the functional profile of CCS in the stomach and small intestine is expected to be different. Investigation of the effect of 561 
composition and level in solid formulations of CCS on solid dosage form disintegration and dissolution based on biorelevant 562 
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approaches would provide an insight on implications for its in vivo functionality. CCS may impact drug’s permeability as it binds to 563 
Ca2+  cations and compromises tight junction integrity; an increased ranitidine permeability in the presence of CCS has been reported 564 
[121]. 565 
5.4.3 Crospovidone 566 
Crospovidone is a water-insoluble nonionic polymer consisted of cross-linked 1-vinyl-2-pyrrolidone monomers (Figure 10). It is 567 
manufactured through a popcorn polymerization technique (proliferous polymerization) of the initial monomer leading to the 568 
formation of porous particles [122]. Crospovidone, used in solid dosage form manufacturing as a disintegrant, acts via a different 569 
mechanism than the swelling starches. When compaction force is applied, the polymer deforms. Upon contact with water, it adsorbs 570 
water via capillary action and regains its normal structure releasing an amount of energy capable to break the tablet. This shape 571 
recovery was confirmed with MRI as a uni-directional expansion of tablet was observed [112].Crospovidone is considered an 572 
excellent excipient leading to fast disintegration without compromising dissolution due to its inability to form a gel [123]. Several 573 
grades of crospovidone are available on market differing in particle size distribution (standard, fine, superfine or micronized powder), 574 
bulk density, hydration capacity and peroxide specifications. 575 
Molecular Properties 576 
Crospovidone is not substituted and lacks of ionizable groups. Therefore, molecular properties of crospovidone are unlikely to 577 
affect excipient’s functionality. Residual peroxides, though, in crospovidone may affect the stability of oxygen sensitive drugs [49]. 578 
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Particle Properties 579 
Monographs define crospovidone into two broad particle size types: A (coarser than 50 μm) and B (finer than 50μm) [124]. For 580 
crospovidone, a wicking agent, particle size relates to particle porosity. As size increases, the intraparticular porosity increases as well 581 
leading to larger water uptake and faster disintegration [125]. A more thorough consideration of crospovidone particle size 582 
specifications could be beneficial. Two equivalent grades of crospovidone powder (Polyplasdone XL and Kollidon CL) with the same 583 
particle size distribution from different suppliers showed differences in particle porosity and water uptake. When dicalcium phosphate 584 
dihydrate was incorporated in HCTZ tablets, the grade with the higher porosity (Polyplasdone XL) dissolved 33% of the drug in 15 585 
minutes while its equivalent (Kollidon CL) released only 18% in the same time. When Kollidon CL (low porosity crospovidone grade) 586 
was compared to a grade of lower particle size from the first supplier (Polyplasdone XL 10), the latter showed increased liquid uptake 587 
and greater HCTZ dissolution than the former [125]. Whether this behavior relates to differences in particle size or variation in 588 
production processes, it designates that equivalent grades according to monograph specifications may have different functionality and 589 
interchange between them should be avoided. 590 
Level 591 
Common levels of crospovidone used in solid dosage forms to provide fast disintegration are 2%-5% w/w [126]. The 592 
disintegration time of tablets containing highly soluble drugs (aspirin and ascorbic acid) and crospovidone decreased until a maximum 593 
crospovidone level of 8% of tablet weight. Levels higher than 8% w/w led to increased disintegration time. When ibuprofen, a poorly 594 
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soluble drug, was formulated with crospovidone in tablet, disintegration time was at its lowest value (30 s) at 8% of tablet weight with 595 
no subsequent increase with increased crospovidone level due to a possible effect of crospovidone concentration on tablet hardness. 596 
Crospovidone levels higher than 8% of tablet weight produce weaker tablets that disintegrate faster [111]. The effect of crospovidone 597 
on tablet hardness and its relation to disintegration should be further investigated. 598 
Biopharmaceutical Properties 599 
pH is unlikely to affect crospovidone functionality, as it is a nonionic non gelling polymer[65]. The swelling values were 600 
found 0.50 mL/g in simulated gastric (0.1 N HCl, pH=1) and intestinal (phosphate buffer, pH=6.8) media (Figure 8) due to the 601 
absence of ionization and the low swelling ability of crospovidone [109]. Water uptake of disintegrant powder was different in the two 602 
media, with values of 0.32 g/s and 0.52 g/s in the gastric and the intestinal media, respectively, due to a potential uncoiling of the 603 
chain in acidic medium [109]. This difference, though, was annihilated in compacts containing spironolactone, diluent-binder, 604 
disintegrant and lubricant and water sorption of these formulations was unaffected by the different pH. Disintegration times were 605 
higher (500 s and 350 s in 0.1 N HCl pH 1 and phosphate buffer pH 6.8, respectively) for lubricated compacts (with magnesium 606 
stearate) when compared to the unlubricated ones (150 s in both media). For lubricated compacts, higher disintegration time was 607 
observed in gastric media than in intestinal media because of the combination of uncoiled crospovidone chains and reduced water 608 
penetration caused by the hydrophobic lubricant [109]. 609 
. 610 
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6. Conclusions 611 
Excipients constitute a major component of solid dosage forms and their use covers a variety of functions, from dosage 612 
manufacturing to dosage performance. Their importance as potential causes for final product variability is recognized and efforts in 613 
characterizing their critical material attributes have been made. Despite the rising awareness on excipient variability, few reports are 614 
addressing their role in drug product dissolution. Examining dissolution inconsistencies is essential, since in vitro dissolution testing 615 
constitutes a predictive tool of in vivo performance apart from its role in quality control testing. In this review, potential critical 616 
material attributes of commonly used excipients have been discussed with respect to product performance. Criticality is related to 617 
excipient functionality that can be altered according to product components and physiological conditions. A great effort still needs to 618 
be made to delineate the complex effects of physiological factors on product performance. We conclude that, despite the challenges 619 
imposed, an investigation of the exact excipient mechanisms in drug release is of paramount importance in order to adequately 620 
characterize and optimize excipient properties by incorporating the QbD principles. 621 
622 
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 899 
Figure captions 900 
Figure 1: A. In vitro (dissolution test) and B. in vivo (gastrointestinal environment) factors reported to affect or be affected by the 901 
presence of excipient in the gastrointestinal lumen. 902 
Figure 2: % HCTZ release versus time from tablets containing A: Croscarmellose sodium and Lactose in i. water (light grey bars) and 903 
ii. 0.1N HCl (dark grey bars) B: Croscarmellose sodium and Dicalcium Phosphate (DP) in i. water (light blue bars) and ii. 0.1N HCl 904 
(dark blue bars) (mean ±SD, n=6). [modified from [65]] 905 
Figure 3: Chemical structure of Microcrystalline Cellulose (ChemDraw Professional 15.0). 906 
Figure 4: Chemical structure of Hypromellose (ChemDraw Professional 15.0). 907 
Figure 5: % released vs time and distance from the sample of HPMC 15 cP in stagnant (a.) and 0.5mL/min flow rate (b.) and HPMC 908 
50 cP in stagnant (c.) and 0.5mL/min flow rate (d.) in phosphate buffer (pH 6.8) with UV dissolution imaging (SigmaPlot 13.0). 909 
[modified from [74]] 910 
Figure 6: Chemical structure of Magnesium Stearate and Magnesium Palmitate (ChemDraw Professional 15.0) 911 
Figure 7: Chemical structure of crosslinked Sodium Starch Glycolate (ChemDraw Professional 15.0). 912 
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Figure 8: Swelling values of SSG, CCS and crospovidone after 20 minutes dispersion of 500 mg of each superdisintegrant in 10 mL 913 
of 0.1N HCl (pH=1) (i.) and phosphate buffer (pH=6.8) (ii.) at room temperature. [modified from [109]] 914 
Figure 9: Chemical structure of Croscarmellose sodium (ChemDraw Professional 15.0). 915 
Figure 10: Chemical structure of Crospovidone (ChemDraw Professional 15. 916 
917 
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Tables 918 
Table 1: Material properties related to excipient variability 919 
 Diluents Binders Lubricants Disintegrants 
Lactose DP MCC HPMC Magnesium 
Stearate 
SSG CCS Crospovidone 
Molecular 
Properties 
Composition             
Hydration            
Structural 
Properties 
Polymorphism             
Particle 
Properties 
Particle size                
Surface area               
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Size distribution              
Level                 
DP: Dicalcium Phosphate, MCC: Microcrystalline Cellulose, HPMC: Hydroxypropyl Methylcellulose (Hypromellose), SSG: Sodium Starch Glycolate, CCS: Croscarmellose 920 
Sodium 921 
922 
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